UM researcher uses stem cells to fight Alzheimer’s
The promise of Neuralstem’s neural stem cell platform technology to treat neurodegenerative disorders, including ALS and Alzheimer’s disease, is the focus of this feature story on the clinical and pre-clinical work underway by NSI-566/ALS principal investigator, Eva L. Feldman, MD, PhD and her team at University of Michigan. “When you get something that works so beautifully (like this experiment), you can quickly see its translational potential. I am looking at a mouse but some day I could be looking at a man. As a clinician scientist, those are the moments you live for,” Dr. Feldman said, regarding her team’s study transplanting Neuralstem’s NSI-532.IGF cells in an animal model of Alzheimer’s disease, with data presented in October at The Congress of Neurological Surgeons Annual Meeting.
UCSD, other stem cell clinics get millions
Report on $8 million grant funding by the California Institute for Regenerative Medicine (CIRM) to three academic medical centers, including UC San Diego whose proposal is reported to support two stem cell-based clinical trials.
With three first-in-human trials, therapeutic stem cell science takes a bold step
University of California, San Diego Health Sciences reports on the first of four patients, who was treated in late September 2014, in the commencement of Neuralstem’s Phase I NSI-566/chronic spinal cord injury (cSCI) trial. The Science Daily story reviews this first FDA-approved trial for cSCI as one of three ground-breaking stem cell efforts underway at UCSD, supported by the Sanford Stem Cell Clinical Center.
“After the Ice Bucket” - Neuralstem NSI-566/ALS Interview with Richard Garr
Neuralstem's President and CEO, Richard Garr, sets out the company’s progress towards its goal of creating a neural stem cell therapy that will make ALS a manageable chronic disease and give patients a normal lifespan and good quality of life in this nearly six-minute TV segment, one of four on the future of ALS research produced by BioCentury in partnership with WUSA9, the CBS affiliate in Washington, D.C. Mr. Garr gives a thorough overview of NSI-566/ALS, including the neural stem cells; specially designed surgical devices used for the world’s first intraspinal injections; “rescue, nurture and integrate” treatment benefits, and Phase I final cohort three-year results from peer-reviewed, published data. NSI-566/ALS Phase II trials concluded final surgeries in July 2014.
Spinal gap: Neuralstem goes into chronic injuries phase I, first ever cleared by FDA
Neuralstem’s President and CEO, Richard Garr, is interviewed in this cover story reporting on the promise of Neuralstem’s NSI-566/chronic spinal cord injury (cSCI) Phase I trial, now underway at the University of California, San Diego School of Medicine. This trial, like Neuralstem’s ongoing NSI-566/ALS trials, represents the first FDA-approved stem cell trial for the indication. While both trials use the same cells and similar procedure, Mr. Garr explains that in addition to neurotrophic factors, in spinal cord injury patients the NSI-566 mechanism of action includes rebuilding neural circuitry for structural repair, “literally bridging the gap… trying to rebuild the circuitry in the gap so that the signal can come through, down the spinal cord.”
- Opinion: This tiny biotech company takes the real ice bucket challenge
- Research making ALS less of a mystery
- NSI-566/ALS Patient Ted Harada Interview
- UCSD Looking For Spinal Cord Injury Patients To Test Stem Cell Treatment
- Clinical trial to investigate safety of neural stem cell transplantation in patients with spinal cord injuries